
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; and IM-3050, a clinical-stage FAP-targeted radioligand therapy. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.
As a member of Immunome’s Legal team, the Clinical Contracts Counsel will play a critical role in supporting the Company’s clinical contracting needs. This position is hands-on and execution-focused, with responsibility for drafting, negotiating, and managing a broad range of clinical and operational agreements that enable Immunome’s research, development, and corporate objectives.
The ideal candidate is solutions-oriented, highly organized, and collaborative, with a strong internal client-service mindset. Experience negotiating clinical trial agreements is required as the Clinical Contracts Counsel will be expected to hit the ground running. This individual will bring demonstrated experience managing contract workflows, developing and maintaining contract templates and playbooks, and supporting contract lifecycle management systems. Reporting to the Senior Director, Contracts Counsel, the Clinical Contracts Counsel will work closely with cross-functional partners to protect the Company’s legal interests while facilitating efficient, practical, and business-aligned contracting processes.
Washington State Pay Range
$205,105—$225,827 USD
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish).

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.